CASE 4 44 yo man HIV positive 2010 CD4 400 on diagnosis Initiated Abacavir/3TC/Dolutegravir in 2011 1/2013 CD4 600 HIV viral load<40 Normal liver enzymes.

Slides:



Advertisements
Similar presentations
Hepatitis c and tuberculosis Tumelo Roestoff FCP(SA) Fellow of Gastroenterology Charlotte Maxeke Johannesburg Academic Hospital.
Advertisements

Edited by Morris Sherman MD BCh PhD FRCP(C) Associate Professor of Medicine University of Toronto Protease Inhibitors in Chronic Hepatitis C: An Update.
Line Efficiency     Percentage Month Today’s Date
21/05/20151 THE WRONG END OF THE NEEDLE DR M G ASHTON CONSULTANT GASTROENTEROLOGIST CHESTERFIELD ROYAL HOSPITAL.
 During his annual physical in Dec 2007, Mr. A, a 42 y old pilot, presented with elevated liver enzymes and positive antibodies to HCV.  He had no symptoms.
+ Understanding HIV-Related Lab Tests Jordan E. Lake, MD, MSc AAHU August 27, 2014.
CASE 2 49 yo man HIV positive 16 yrs. ago CD4 15 on diagnosis Disseminated cutaneous Kaposi’s Sarcoma.
VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.
CASE 3 63 yo man HIV positive G1a chronic Hepatitis C… Recent HIV history TDF/FTC/RTV/Atazanavir with CD4 480 and HIV viral load
NYU Medical Grand Rounds Clinical Vignette Alexander Jow, PGY-3 February 21, 2012 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
CASE 3 43 yo man HIV+ since 2005 CD4 nadir 190 Baseline genotype…clear.
Clinical case 19 Lin, I-Yao (Sally). Case 19 Having been confined in the hospital for almost a month due recurrent pneumonia, Mr. XXX, 42 y/o, married,
CASE 3 48 yo man HIV positive/HEP C positive 12 yrs ago Tenofovir/FTC/RTV/Lopinavir x 7 yrs CD4 310/40% HIV Viral Load
+ Understanding HIV-Related Lab Tests Jordan E. Lake, MD, MSc AAHU Sept 1, 2015.
VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.
CASE 4 53 yo man HIV+ since 1989 CD4 nadir 220. CASE 4 DATEREGIMENCREATININE 1990AZT AZT/DDI AZT/3TC/IDV AZT/3TC/NFV TDF/AZT/3TC/NFV102.
EUROPE Nov 27 –Dec 10 November 27 - Dec 10.
This is an example text TIMELINE PROJECT PLANNING DecOctSepAugJulyJuneAprilMarchFebJanMayNov 12 Months Example text Go ahead and replace it with your own.
CASE 2 58 yo man IVDU in past….last used 35 yrs ago Genotype 1a Chronic Hepatitis C Type II Diabetes Private drug plan coverage.
CASE 3 48 yo man HIV positive/HEP C positive 12 yrs. ago Tenofovir/FTC/RTV/Lopinavir x 7 yrs. CD4 310/40% HIV Viral Load
David A. Weinstein, M.D, M.M.Sc. Director; Glycogen Storage Disease Program Milan Italy October 2, 2010 Gene Therapy in the Canine Model of GSD Ia.
CASE 2 54 yo man…HIV PCP Cryptospordiasis Chronic HepC Genotype 1a Biopsy… 2/4 activity, 3/4scarring CD4 40 No baseline genotype.
CASE 1 54 yo man HIV Generalized Anxiety/OCD VL 15,185 CD4 ranges from Baseline Genotype clear.
CASE 1 54 yo man HIV positive 8 yrs ago Tenofovir/FTC/RTV/Atazanavir x 4 yrs Previously documented NNRTI resistance with Y181C, G190A,and mixed m184v/wt.
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Maternal Toxicity Management
Hepatitis C in MSMs; a review of testing practices in the GUIDe clinic & a description of recent cases N. Lynn*, J Dean**, e quinn**, G Farrell*, C Murray*
Jan 2016 Solar Lunar Data.
ARV-trial.com Switch to ATV/r + 3TC ATLAS-M Study.
Maternal Toxicity Management
Maternal Toxicity Management
CASE 2 53 yo man HIV CD4 340/16% (Nadir) VL 30,100 c/ml.
Q1 Jan Feb Mar ENTER TEXT HERE Notes
Average Monthly Temperature and Rainfall

History 56 y/o male from Cuba newly diagnosed with hepatitis C genotype 2b in Jan 2008 No symptoms of decompensation.
2017 Jan Sun Mon Tue Wed Thu Fri Sat
Gantt Chart Enter Year Here Activities Jan Feb Mar Apr May Jun Jul Aug
Q1 Q2 Q3 Q4 PRODUCT ROADMAP TITLE Roadmap Tagline MILESTONE MILESTONE
Free PPT Diagrams : ALLPPT.com

FY 2019 Close Schedule Bi-Weekly Payroll governs close schedule

PBIS Update November 2005.
Jan Sun Mon Tue Wed Thu Fri Sat
2009 TIMELINE PROJECT PLANNING 12 Months Example text Jan Feb March

Electricity Cost and Use – FY 2016 and FY 2017

Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Comparison of NNRTI vs PI/r
Text for section 1 1 Text for section 2 2 Text for section 3 3
Q1 Q2 Q3 Q4 PRODUCT ROADMAP TITLE Roadmap Tagline MILESTONE MILESTONE
Free PPT Diagrams : ALLPPT.com
JUNE 2010 CALENDAR PROJECT PLANNING 1 Month MONDAY TUESDAY WEDNESDAY
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3

2009 TIMELINE PROJECT PLANNING 12 Months Example text Jan Feb March
Q1 Q2 Q3 Q4 PRODUCT ROADMAP TITLE Roadmap Tagline MILESTONE MILESTONE
Pilot of revised survey
Sequencing cohorts Open-label Design W8 W12 ≥ 18 years
Presentation transcript:

CASE 4 44 yo man HIV positive 2010 CD4 400 on diagnosis Initiated Abacavir/3TC/Dolutegravir in /2013 CD4 600 HIV viral load<40 Normal liver enzymes

CASE 4 FEB 2013 Acute Hepatitis C…ALT>1000 Genotype 4 HCVRNA 1.7 x 10e6

CASE 4 Remainder of 2013 ALT decreased to HCVRNA 1.02x 10e5 (may/13) to 2.1 x 10e6 (Aug 2013) Diagnosis…Chronic Hepatitis C

CASE 4 Jan-July 2014 ALT decreased to CD4 600 HIV Viral Load<40

CASE 4 AUG 2014 ALT increased to 280 CD4 600 HIV Viral Load<40

CASE 4 NOV 2014 ALT down from 280 to 80 We discussed initiating therapy with Sofosbuvir/RBV x 24 weeks

CASE 4 DEC 2014 ALT 45 Baseline HCVRNA done Initiated therapy with Sofosbuvir/RBV x 24 weeks

CASE 4 JAN 2015 Week 2 of Hep C therapy with SOF/RBV ALT 30 Retrospectively baseline HCVRNA was undetectable prior to therapy despite elevated ALT!!!

CASE 4 JAN 2015 Went back to HIV viral load bloods that were stored from August/14 and late November/14 and ran HCVRNAs

CASE 4 Jan-Feb 2015 Baseline HCVRNA in x 10 e6 Aug/14 8.2x 10e4 Nov/ x 10e1 Dec/14 (pre-Rx) undetectable

CASE 4 Feb 2015 Self clearance of Hep C 20 months post acute Hepatitis C!!! Decided to finish SOF/RBV therapy as side effect free in case there would be a rebound of HCVRNA We could have discontinued but would then only have 18 weeks of therapy left if we had to restart